Suppr超能文献

裸盖菇素疗法与神经性厌食症:针对研究人员和临床医生的安全性考量的叙述性综述

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.

作者信息

Downey Amanda E, Chaphekar Anita V, Woolley Joshua, Raymond-Flesch Marissa

机构信息

Department of Pediatrics, University of California, San Francisco, CA, USA.

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.

出版信息

J Eat Disord. 2024 Apr 24;12(1):49. doi: 10.1186/s40337-024-01005-z.

Abstract

BACKGROUND

Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities. The purpose of this review is to describe how the common physiologic adverse effects of psilocybin may impact medical complications experienced by individuals with AN in clinical trials of psilocybin therapy.

MAIN BODY

The physiologic underpinnings of common adverse effects following psilocybin administration are described, including tachycardia, hypertension, electrocardiogram changes, nausea, headache, and lightheadedness. These anticipated physiologic changes are described in relation to the common medical correlates seen in individuals with AN. Risk mitigation strategies for each adverse effect are proposed.

CONCLUSION

Early evidence suggests that psilocybin therapy is well-tolerated in individuals with AN. Understanding the unique medical complications of AN, and how they may be impacted by common physiologic adverse effects of psilocybin administration, leads to tailored risk mitigation strategies to enhance safety and tolerability of this novel intervention.

摘要

背景

目前正在进行使用裸盖菇素疗法治疗神经性厌食症(AN)的临床试验。在可能存在独特医学脆弱性的神经性厌食症患者中,裸盖菇素的安全性和耐受性至关重要。本综述的目的是描述裸盖菇素常见的生理不良反应如何在裸盖菇素疗法的临床试验中影响神经性厌食症患者所经历的医学并发症。

主体

描述了服用裸盖菇素后常见不良反应的生理基础,包括心动过速、高血压、心电图变化、恶心、头痛和头晕。这些预期的生理变化与神经性厌食症患者中常见的医学相关情况相关。针对每种不良反应提出了风险缓解策略。

结论

早期证据表明,神经性厌食症患者对裸盖菇素疗法耐受性良好。了解神经性厌食症独特的医学并发症,以及它们如何受到服用裸盖菇素常见生理不良反应的影响,有助于制定针对性的风险缓解策略,以提高这种新型干预措施的安全性和耐受性。

相似文献

2
Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".
Front Psychiatry. 2021 Oct 20;12:735523. doi: 10.3389/fpsyt.2021.735523. eCollection 2021.
3
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Nat Med. 2023 Aug;29(8):1947-1953. doi: 10.1038/s41591-023-02455-9. Epub 2023 Jul 24.
4
Psilocybin history, action and reaction: A narrative clinical review.
J Psychopharmacol. 2023 Sep;37(9):849-865. doi: 10.1177/02698811231190858. Epub 2023 Aug 31.
5
Psilocybin for anorexia nervosa: If it helps, let's learn how.
Med. 2023 Sep 8;4(9):581-582. doi: 10.1016/j.medj.2023.08.003.
6
Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.
Am J Ther. 2024;31(2):e121-e132. doi: 10.1097/MJT.0000000000001724.
7
Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study.
Focus (Am Psychiatr Publ). 2024 Jul;22(3):381-387. doi: 10.1176/appi.focus.24022013. Epub 2024 Jun 28.
8
Therapeutic use of psilocybin: Practical considerations for dosing and administration.
Front Psychiatry. 2022 Dec 1;13:1040217. doi: 10.3389/fpsyt.2022.1040217. eCollection 2022.
9
Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
Cancer. 2024 Apr 1;130(7):1137-1146. doi: 10.1002/cncr.35010. Epub 2023 Dec 18.
10
Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2024 Apr 1;7(4):e245960. doi: 10.1001/jamanetworkopen.2024.5960.

本文引用的文献

1
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
JAMA. 2023 Sep 5;330(9):843-853. doi: 10.1001/jama.2023.14530.
2
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Nat Med. 2023 Aug;29(8):1947-1953. doi: 10.1038/s41591-023-02455-9. Epub 2023 Jul 24.
3
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.
J Psychopharmacol. 2023 Jul;37(7):707-716. doi: 10.1177/02698811231179910. Epub 2023 Jun 8.
4
Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis.
Cureus. 2023 May 7;15(5):e38669. doi: 10.7759/cureus.38669. eCollection 2023 May.
5
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Front Psychiatry. 2023 Feb 10;13:1076459. doi: 10.3389/fpsyt.2022.1076459. eCollection 2022.
6
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders.
Am J Psychiatry. 2023 Feb 1;180(2):167-171. doi: 10.1176/appi.ajp.23180001.
8
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443.
9
Medical Management of Restrictive Eating Disorders in Adolescents and Young Adults.
J Adolesc Health. 2022 Nov;71(5):648-654. doi: 10.1016/j.jadohealth.2022.08.006. Epub 2022 Sep 2.
10
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
J Psychopharmacol. 2022 Oct;36(10):1100-1117. doi: 10.1177/02698811221116926. Epub 2022 Aug 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验